The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
Open accessAbstract
OBJECTIVE: To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal insulin (≥42 units/day) plus mealtime insulin. RESEARCH DESIGN AND METHODS: EDITION 1 (NCT01499082) was a 6-month, multinational, open-label, parallel-group study. Adults with glycated hemoglobin A1c (HbA1c) 7.0–10.0% (53–86 mmol/mol) were randomized to Gla-300 or Gla-100 once daily with dose titration seeking fasting plasma glucose 4.4–5.6 mmol/L. Primary end point was HbA1c change from baseline; main secondary end point was percentage of participants with one or more confirmed (≤3.9 mmol/L) or severe nocturnal hypoglycemia from week 9 to month 6. RESULTS: Participants (n = 807) had mean age 60 years, diabetes duration 16 years, BMI 36.6 kg/m2, and HbA1c 8.15% (65.6 mmol/mol). HbA1c reduction was equivalent between regimens; least squares mean difference –0.00% (95% CI –0.11 to 0.11) (–0.00 mmol/mol [–1.2 to 1.2]). Fewer participants reported one or more confirmed (≤3.9 mmol/L) or severe nocturnal hypoglycemic events between week 9 and month 6 with Gla-300 (36 vs. 46% with Gla-100; relative risk 0.79 [95% CI 0.67–0.93]; P < 0.005); nocturnal hypoglycemia incidence and event rates were also lower with Gla-300 in the first 8 weeks of treatment. No between-treatment differences in tolerability or safety were identified. CONCLUSIONS: Gla-300 controls HbA1c as well as Gla-100 for people with type 2 diabetes treated with basal and mealtime insulin but with consistently less risk of nocturnal hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00013 · Cited by 4,615
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Self-citationPsychological Insulin Resistance in Patients With Type 2 Diabetes
Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2543 · Cited by 551
When oral agents fail: practical barriers to starting insulin
Korytkowski, M. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0802173 · Cited by 448
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414
Self-citationBecker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407
Bradley, C., & Lewis, K. S. (1990) · Diabetic Medicine · doi:10.1111/j.1464-5491.1990.tb01421.x · Cited by 379
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Garber, A. J., King, A. B., Prato, S. D., Sreenan, S., Balci, M. K., Muñoz-Torres, M., Rosenstock, J., Endahl, L. A., Francisco, A. M. O., & Hollander, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60205-0 · Cited by 325
Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60485-7 · Cited by 305
Gerstein, H. C., Yale, J. ‐., Harris, S. B., Issa, M., Stewart, J. A., & Dempsey, E. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01881.x · Cited by 197
Gough, S. C. L., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., & Bergenstal, R. M. (2013) · Diabetes Care · doi:10.2337/dc12-2329 · Cited by 150
Insulin detemir: from concept to clinical experience
Home, P., & Kurtzhals, P. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.3.325 · Cited by 139
Self-citationInsulin Preparations with Prolonged Effect
Owens, D. R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0068 · Cited by 130
Kurtzhals, P. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802746 · Cited by 116
Bergenstal, R. M., Rosenstock, J., Arakaki, R. F., PRINCE, M. J., Qu, Y., Sinha, V. P., Howey, D. C., & Jacober, S. J. (2012) · Diabetes Care · doi:10.2337/dc12-0060 · Cited by 115
Aschner, P. J., Chan, J. C. N., Owens, D. R., Picard, S., Wang, E., Dain, M., Pilorget, V., Echtay, A. S., & Fonseca, V. A. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60439-5 · Cited by 111
Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
Steinstraesser, A., Schmidt, R., Bergmann, K., Dahmen, R., & Becker, R. H. A. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12283 · Cited by 107
Fritsche, A., Larbig, M., Owens, D. R., Häring, H., & on behalf of the GINGER study group (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01165.x · Cited by 104
Riddle, M. C., Rosenstock, J., Vlajnic, A., & Gao, L. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12225 · Cited by 96
Self-citationThe reality of glycaemic control in insulin treated diabetes: defining the clinical challenges
Davies, M. J. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802745 · Cited by 94
A Measure of Treatment Satisfaction Designed Specifically for People with Insulin‐dependent Diabetes
Lewis, K. S., Bradley, C., Knight, G. C., Boulton, A. J. M., & Ward, J. D. (1988) · Diabetic Medicine · doi:10.1111/j.1464-5491.1988.tb00976.x · Cited by 84
Meneghini, L., Mersebach, H., Kumar, S., Svendsen, A. L., & Hermansen, K. (2011) · Endocrine Practice · doi:10.4158/ep10367.or · Cited by 79
Bolli, G. B., Andreoli, A. M., & Lucidi, P. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0039 · Cited by 33
Self-citationThe ORIGIN Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2238 · Cited by 30
Riddle, M. C., Gerstein, H. C., Dyal, L., et al. (2013) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-91132 · Cited by 23
Self-citationPeyrot, M. F., & Rubin, R. R. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0128 · Cited by 21
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
Cited by
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Blonde, L., Khunti, K., Harris, S. B., Meizinger, C., & Skolnik, N. S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0805-y · Cited by 714
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Metadata
- Authors
- Riddle, M. C., Bolli, G. B., Ziemen, M., Muehlen-Bartmer, I., Bizet, F., & Home, P. D.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-09-10
- Volume
- 37
- Issue
- 10
- Pages
- 2755-2762
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2100633491
- Cited by
- 354
- References
- 36
- FWCI
- 29.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.